Enterprise Value Assessment Of Gene Sequencing

Compared with modern medical treatment,precision medicine pays more attention to the depth of disease and pinpoint accuracy of medicine.With the increasing emphasis on precision medical development all over the world,global industry scale has grown rapidly.As the cornerstone of precision medicine,gene sequencing is very important.Medical application services are currently more active and more potential,such as NIPT,genetic diagnosis,and tumor diagnosis.At the same time,gene sequencing technology is also widely used in other fields such as agriculture and microbiology,which will bring about major changes in agricultural development and environmental protection.The vast market space and vigorous development of the gene sequencing industry have attracted many companies to enter the industry.How to assess the value of these companies which are in different market segments or different positions of the industrial chains and different development levels more accurately is an urgent problem for market investors.Based on the previous studies and considering high-tech,high-innovation,high-risk,high-investment capital and high intangible assets characteristics of gene sequencing enterprises,this paper compares the advantages and disadvantages and limitations of traditional valuation methods,and expounds real options valuation method is suitable for gene sequencing enterprises with the coming value of decision-making flexibility and future growth opportunities,then chooses real options method as a supplement to traditional valuation methods,combining EVA two-stage valuation model and B-S model as comprehensive pricing model to assess the overall value of gene sequencing companies from realistic value and potential value,finally verifies the applicability and rationality of the comprehensive model by case studies.We draw a conclusion that this comprehensive pricing model is more pragmatic than traditional valuation methods which will underestimate the value of gene sequencing enterprises,it contributes to providing more accurate and reliable basis for market investors,and also improving value evaluation system of gene sequencing enterprises,and providing a new attempt for the application of real options method in the gene sequencing industry.